Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Michigan
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Science to Targeted Exposure Analysis
For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical treatments and their associated risks. This legacy established a framework for communicating complex biomedical concepts to diverse audiences, emphasizing clarity and accessibility. Within this tradition, the focus has often been on broad therapeutic benefits and population-level safety profiles, providing a baseline of knowledge that informs both clinical practice and patient awareness. As this informational heritage evolves, a natural progression emerges toward more specific, context-driven inquiries. One such area of heightened scrutiny involves the intersection of pharmaceutical therapies and occupational or environmental exposure concerns. In particular, the administration of biologic agents for chronic conditions has prompted detailed examination of potential downstream risks that extend beyond the immediate clinical setting. This shift in focus requires a careful pivot from general health literacy to the practical implications of exposure in real-world scenarios, including workplace and legal contexts. The transition from broad health science communication to targeted exposure analysis is exemplified by the case of Tysabri, a medication used in the management of certain autoimmune disorders. Here, the general health narrative gives way to a concentrated examination of Progressive Multifocal Leukoencephalopathy risk, a serious neurological condition associated with the drug. This pivot underscores the need for specialized legal and medical guidance, particularly regarding statutes of limitations in jurisdictions such as Michigan, where affected individuals may seek recourse.
Tysabri and PML: Medical Evidence and Risk Factors
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease. Its prescribing information carries a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients without overt immunosuppression have developed the disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies three established risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but typically includes subacute onset of neurologic deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can progress rapidly, the label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, adverse-event reports submitted to the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, gait disturbance, balance disorder, cognitive disorder, and muscular weakness among the most frequently reported events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the range of neurologic symptoms that may be observed in patients, some of which overlap with early PML manifestations.
Mechanism of PML and Legal Implications in Michigan
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents lymphocyte migration across the blood-brain barrier, reducing immune surveillance in the central nervous system. This impaired immune surveillance allows latent JC virus, which is carried asymptomatically by a majority of adults, to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, as this indicates prior exposure to the virus. Duration of therapy beyond two years further increases risk, likely due to prolonged immune suppression within the CNS. Prior use of immunosuppressants, such as mitoxantrone or cyclophosphamide, compounds this risk by further compromising immune function. For patients in Michigan who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability claim. In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For claims involving defective drugs, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the PML. Given that PML symptoms can be subtle and initially mistaken for a multiple sclerosis relapse, the date of diagnosis—confirmed by MRI and JCV testing—often marks the point of discovery. Patients should consult with an attorney promptly to ensure their claim is filed within the applicable time frame. Adequacy of warnings is a central issue in such claims. The Tysabri label includes a boxed warning and a restricted distribution program called TOUCH, which requires prescribers and patients to acknowledge the PML risk. However, plaintiffs may argue that the warnings were insufficient to inform patients of the magnitude of risk, particularly for those with no prior immunosuppressant use or with shorter treatment durations. The label states that risk factors should be considered, but it does not provide quantitative risk estimates for all patient subgroups. Additionally, the FAERS data show that many patients continue to experience neurologic adverse events, raising questions about whether monitoring and early detection are consistently implemented. The timeline between Tysabri exposure and documented harm is critical. PML typically develops after months to years of treatment, with the highest risk after 24 or more infusions. For patients who develop PML, the interval between symptom onset and diagnosis can be weeks, during which irreversible brain damage may occur. Early diagnosis and immune reconstitution—often through plasma exchange to accelerate Tysabri clearance—can improve outcomes, but many patients still suffer severe disability or death. This latency period complicates legal claims because the injury may not manifest until years after the initial prescription, and the statute of limitations may be triggered by the date of diagnosis rather than the date of first exposure. In summary, Tysabri-associated PML is a devastating complication with well-characterized risk factors and a plausible mechanistic basis. Patients in Michigan who have been harmed should be aware of the three-year statute of limitations and the importance of timely legal consultation. The adequacy of warnings, the role of the TOUCH program, and the timeline from exposure to harm are all relevant factors in evaluating potential claims.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in Michigan?
In Michigan, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For Tysabri-related PML, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the PML. The date of diagnosis, confirmed by MRI and JCV testing, often marks the point of discovery. It is crucial to consult an attorney promptly to ensure the claim is filed within the applicable time frame.
What are the risk factors for developing PML from Tysabri?
The Tysabri label identifies three established risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.